Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.

ABSTRACT: This study demonstrates real-world effectiveness of teriparatide in reducing the risk of hip and other fragility fractures. Fracture incidence significantly decreased as adherence and persistence increased for any clinical, vertebral, nonvertebral, and hip fractures among patients who were observed for 2 years after teriparatide initiation.

Introduction

Examine the relationship of treatment adherence and persistence to teriparatide with hip and other fractures.

Methods

Truven MarketScan Research Databases, 2004 through 2014, provided teriparatide users ≥18 years old with continuous coverage 12 months pre- and 24 months post-teriparatide prescription. Adherence (medication possession ratio, MPR) groups were defined as high (≥0.80), medium (0.50 ≤ MPR < 0.80), and low (<0.50).

SUBMITTER: Burge RT 

PROVIDER: S-EPMC5306167 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature